Close

Enox Biopharma, LTD. Announces First Enrollments of A Phase 1a/lb Clinical Trial

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

New Endometrial Cancer Therapy Phase-II Trial Shows Promise

The most recent trial of a new antibody drug...

Duality Looks Out For Hong Kong IPO To Finance ADC Trials

Duality Biotherapeutics from China has gone ahead and filed...

PhotonPharma Secures $2.5 Million in Seed Funding to Advance Clinical Trial for Ovarian Cancer Treatment

PhotonPharma, a cutting-edge biopharmaceutical company based in Fort Collins,...

Enox Biopharma, Ltd., a leader in nitric oxide delivery technology for the prevention of hospital acquired infections announced today the enrollment of the first subjects in a phase 1a/1b study for the evaluation of the safety and tolerability of Nitric Oxide (NO) impregnated urinary catheters. The study primary aim of this first in man study is to assess the safety and tolerability of NO-charged Foley catheters left in place for 7 to 14 days following surgical removal of the prostate. This two-arm study will also measure and compare the biofilm formation on the surface of NO charged versus non-NO charged Foley catheters as well as measure the presence of bacterium in the urine of subjects managed with the different catheter types.

David Greenberg, M.D., Enox’s Chief Medical Officer and a Professor of pediatrics and infectious diseases at Soroka Medical Center in Beer Sheva, Israel, said: “Nitric Oxide is a foundation molecule of the human body’s immune system. This study is the first clinical step towards the use of NO gas to reduce dramatically hospital acquired infections which are also known as nosocomial infections”.

Prof. Jack Baniel, Head of the Urology department at Rabin Medical Center at Beilinson Campus adds: “Nosocomial infections remain a substantial burden on all healthcare systems despite best efforts at hospitals worldwide. The use of urology embedded NO catheters may serve as a major improvement in our goal of dramatically reducing hospital acquired infections”.

Prof Yossef Av Gay, Enox’s founder and professor of microbiology at the University of British Columbia, Canada, states: “The use Enox’s antimicrobial technology is uniquely positioned to address hospital acquired infection by utilizing the natural broad spectrum antimicrobial nitric oxide. Nitric oxide provides alternative means to antibiotics with limited chances of developing antimicrobial resistance.”

About Enox Biopharma, ltd.

Enox Biopharma Ltd. is an emerging biotechnology company with proprietary methods to impregnate nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth – embedding NO into medical devices makes them antimicrobial. Enox’s device technology is applicable to variety of indwelling polymer medical devices including, but not limited to, catheters, endotracheal tubes and central venous catheters and implanted devices. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide

 

Latest stories